Cinclus Pharma's solution
Social/Environmental challenge
Unmet medical need in the treatment of gastroesophageal reflux disease. Currently, >20% of all patients are non-responsive to existing treatment options, resulting in suffering and reduced quality of life.
Increasing AMR: the eradication rate of H. pylori is decreasing globally due to increasing antibiotic resistance. H. pylori is included on WHO’s list of “high priority pathogens” as a bacterium that has the potential to pose a serious threat to public health.
Access gap to innovative medicines: For most innovative medicines, it takes years after market approval in high incomes countries until the product is introduced across low- and middle-income countries.
SDG Contribution
SDG # 3: Better health and well-being for all
Potential contribution: Improving the standard of care in gastric acid related disease, and expanding geographic access outside high income countries
SDG # 3.3: Fighting communicable diseases
Potential contribution: H. pylori eradication and combating antimicrobial resistance
SDG # 3.4: Reducing mortality from non-communicable diseases
Potential contribution: H. pylori infection is the strongest known risk factor for development of gastric cancer
